Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269355 · ClinicalTrials.gov registry record · Phase 2
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
A Phase 2 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT05269355 is a Phase 2 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 359 participants.
The verdict
NCT05269355, a Phase 2 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Interventions
- OTHER Placebo
- DRUG Dacarbazine
- DRUG Unesbulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269355
The ClinicalTrials.gov registry entry for NCT05269355 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05269355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05269355 about?
NCT05269355 is a clinical study titled "A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)". This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
What is the current status of trial NCT05269355?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2022-05-23. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT05269355?
The interventions under investigation include: Placebo (OTHER), Dacarbazine (DRUG), Unesbulin (DRUG).
Who is sponsoring clinical trial NCT05269355?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.